ESMO-MCBS Scorecards

The ESMO-MCBS Scorecards provides a centralised location of cancer medicines that have been scored and published by ESMO.

It includes all cancer medicines approved by the European Medicines Agency (from January 2016) and the US Food and Drug Administration (from January 2020).

ESMO-MCBS Scores

Number of studies

Non-curative setting
5	17
4	95
3	125
2	34
1	19

Curative setting
A	38
C	2

ESMO-MCBS Scores by tumour type

Non-curative setting
Breast Cancer	28
Central Nervous System Malignancies	0
Endocrine Tumours	19
Gastrointestinal Cancers	53
Genitourinary Cancers	51
Gynaecological Malignancies	30
Head and neck cancer	6
Refractory NTRK fusion–positive cancers	2
Sarcoma	10
Skin Cancers	24
TMB-H solid tumours	1
Thoracic Malignancies	65
dMMR/MSI-H solid tumours	1

Curative setting
Breast Cancer	8
Central Nervous System Malignancies	1
Endocrine Tumours	0
Gastrointestinal Cancers	15
Genitourinary Cancers	4
Gynaecological Malignancies	0
Head and neck cancer	0
Refractory NTRK fusion–positive cancers	0
Sarcoma	2
Skin Cancers	8
TMB-H solid tumours	0
Thoracic Malignancies	2
dMMR/MSI-H solid tumours	0

The ESMO-MCBS Scorecards

The ESMO-MCBS Scorecards allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.

ESMO-MCBS V1.1 – Evaluation Forms

Evaluation form 1 Evaluation form 2a Evaluation form 2b Evaluation form 2c Evaluation form 3

Evaluation form 1 For new approaches to adjuvant therapy or new potentially curative therapies

Evaluation form 2a For therapies that are not likely to be curative with primary endpoint of OS with separate sheets for:

Evaluation form 2b For therapies that are not likely to be curative with primary endpoint PFS with separate sheets for:

Evaluation form 2c For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies

Evaluation form 3 For single-arm studies in “orphan diseases” and for diseases with “high unmet need” when primary outcome is PFS or ORR.

Column view

Tested Agent(s)	Combined Agent(s)	Control Arm	Treatment Setting	Tumour Type	Tumour Sub-type	Tumour Sub-group	Trial Name	Score	Scorecard
Lenvatinib	Pembrolizumab	Sunitinib	First-line treatment	Genitourinary Cancers	Renal cell cancer	-	CLEAR	4	PRELIMINARY SCORE Non-Curative OS 6 ADJUSTMENTS FINAL SCORE Non-Curative F1 2
Enfortumab vedotin	-	Investigator-chosen ChT (standard docetaxel, paclitaxel or vinflunine)	Treatment of adult patients who have previously received a platinum-containing chemotherapy and a programmed death receptor-1 or programmed death-ligand 1 inhibitor	Genitourinary Cancers	Urothelial Carcinoma	-	EV-301	4	PRELIMINARY SCORE Non-Curative OS 5 ADJUSTMENTS FINAL SCORE Non-Curative F1 2
Nivolumab	Fluoropyrimidine and platinum ChT (FOLFOX or CAPOX)	ChT (FOLFOX or CAPOX)	First‑line treatment of adult patients with HER2‑negative whose tumours express PD-L1 with a CPS ≥5	Gastrointestinal Cancers	Gastric or gastro-oesophageal junction cancer and oseophageal adenocarcinoma	HER2- PD-L1 CPS ≥5	CHECKMATE-649	4	PRELIMINARY SCORE Non-Curative OS 5 ADJUSTMENTS FINAL SCORE Non-Curative F1 2
Pembrolizumab	-	ChT ((5-fluorouracil–based therapy with or without bevacizumab or cetuximab)	First‑line treatment of metastatic microsatellite instability‑high (MSI‑H) or mismatch repair deficient (dMMR) colorectal cancer in adults.	Gastrointestinal Cancers	Colorectal Cancer	dMMR or MSI-H	KEYNOTE-177	4	PRELIMINARY SCORE Non-Curative OS 6 ADJUSTMENTS FINAL SCORE Non-Curative F1 2
Pembrolizumab	ChT with our without bevacizumab	Placebo + ChT with our without bevacizumab	First-line treatment	Gynaecological Malignancies	Cervical Cancer	PD-L1 (CPS ≥1)	KEYNOTE-826	4	PRELIMINARY SCORE Non-Curative OS 5 ADJUSTMENTS FINAL SCORE Non-Curative F1 2
Pembrolizumab	Cisplatin and 5-FU ChT	Placebo + cisplatin and 5-FU ChT	First-line treatment	Gastrointestinal Cancers	Oesophageal or gastroesophageal carcinoma	HER2- GEJ PD-L1 CPS ≥10	KEYNOTE-590	4	PRELIMINARY SCORE Non-Curative OS 5 ADJUSTMENTS FINAL SCORE Non-Curative F1 2
Pembrolizumab	Cisplatin and 5-FU ChT	Placebo + cisplatin and 5-FU ChT	First-line treatment	Gastrointestinal Cancers	Oesophageal or gastroesophageal carcinoma	HER2- GEJ PD-L1 (squamous cell) CPS ≥10	KEYNOTE-590	4	PRELIMINARY SCORE Non-Curative OS 5 ADJUSTMENTS FINAL SCORE Non-Curative F1 2
Tebentafusp	-	Investigator Choice (either dacarbazine, ipilimumab or pembrolizumab)	Treatment of human leukocyte antigen (HLA)-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma	Skin Cancers	Uveal melanoma	HLA-A*0201positive	IMCgp100-202	4	PRELIMINARY SCORE Non-Curative OS 5 ADJUSTMENTS FINAL SCORE Non-Curative F1 2
Relugolix	-	Leuprolide	Therapy with either prostate cancer recurrence following radiation or surgery or newly diagnosed castration-sensitive advanced prostate cancer	Genitourinary Cancers	Prostate cancer	-	HERO	4	PRELIMINARY SCORE Non-Curative OS 5 ADJUSTMENTS FINAL SCORE Non-Curative F1 2
Nivo/Ipi (nivolumab and ipilimumab)	-	ChT	First-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression ≥1%	Gastrointestinal Cancers	Oesophageal Cancer	PD-L1 expression ≥1%	CheckMate 648	4	PRELIMINARY SCORE Non-Curative OS 5 ADJUSTMENTS FINAL SCORE Non-Curative F1 2

1
...
6
7
8
9 of 10
10

Column view

	Tested Agent(s)	Combined Agent(s)	Control Arm	Treatment Setting	Tumour Type	Tumour Sub-type	Tumour Sub-group	Trial Name	Ref.	Score	esmo.mcbs.table.heading.visualisation	esmo.mcbs.table.heading.visualisation

The ESMO-MCBS Scorecards provides a centralised location of cancer medicines that have been scored and published by ESMO.

The ESMO-MCBS Scorecards

Evaluation form 1 For new approaches to adjuvant therapy or new potentially curative therapies

Evaluation form 2a For therapies that are not likely to be curative with primary endpoint of OS with separate sheets for:

Evaluation form 2b For therapies that are not likely to be curative with primary endpoint PFS with separate sheets for:

Evaluation form 2c For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies

Evaluation form 3 For single-arm studies in “orphan diseases” and for diseases with “high unmet need” when primary outcome is PFS or ORR.

My watchlist

PRELIMINARY SCORE

ADJUSTMENTS

FINAL SCORE

PRELIMINARY SCORE

ADJUSTMENTS

FINAL SCORE

PRELIMINARY SCORE

ADJUSTMENTS

FINAL SCORE

PRELIMINARY SCORE

ADJUSTMENTS

FINAL SCORE

PRELIMINARY SCORE

ADJUSTMENTS

FINAL SCORE

PRELIMINARY SCORE

ADJUSTMENTS

FINAL SCORE

PRELIMINARY SCORE

ADJUSTMENTS

FINAL SCORE

PRELIMINARY SCORE

ADJUSTMENTS

FINAL SCORE

PRELIMINARY SCORE

ADJUSTMENTS

FINAL SCORE

PRELIMINARY SCORE

ADJUSTMENTS

FINAL SCORE